Length of Royalty Obligations Sample Clauses

Length of Royalty Obligations. Bio-Management's obligation to pay royalties with respect to each Product in such country shall commence on the First Commercial Date for such Product in such country, and shall continue for such Product in such country until the date ten (10) years from the First Commercial Sale.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Length of Royalty Obligations. Each party’s obligations to pay royalties (including without limitation percentages of Sublicense Income) with respect to each Product in each country shall commence on the Royalty Commencement Date for such Product in such country, and shall continue for such Product in such country until (i) [**************************], or (ii) [*************************************].
Sample 1Sample 2See All (4)
Length of Royalty Obligations. Anthera’s obligation to pay royalties with respect to each Licensed Product in each country in the Territory shall commence on the date of the First Commercial Sale of such Licensed Product in such country and shall expire upon the later of (a) ten (10) years following the date of the First Commercial Sale of such Licensed Product in such country, and (b) the first date on which generic version(s) of the applicable Licensed Product achieve a total market share, in the aggregate, of twenty-five percent (25%) or more of the total unit sales of wholesalers to pharmacies of Licensed Product and all generic versions combined in the applicable country.
Sample 1Sample 2
Length of Royalty Obligations. NTI’s obligation to pay royalties to Institute under Section 5.4 shall commence on the date of the First Commercial Sale of the applicable Product in such country or territory and shall expire upon the later of (a) ten (10) years following the date of the First Commercial Sale of such Product in such country, or (b) the date on which the last Valid Claim within the Program Patents in which Institute has an ownership interest or Institute Patent Rights covering the composition, method of making, or method of using the applicable Product expires in such country or territory. * * * Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.
Sample 1
Length of Royalty Obligations. Anthera’s obligation to pay royalties with respect to each Licensed Product in each country in the Territory shall commence on the date of the First Commercial Sale of such Licensed Product in such country and shall expire upon the later of (a) twelve (12) years following the date of the First Commercial Sale of such Licensed Product in such country, and (b) the expiration of the last Valid Claim. * Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.
Sample 1
Length of Royalty Obligations. Cell-Matrix's obligation to pay royalties with respect to each Product in such country shall commence on the First Commercial Sale for such Product in such country, and shall continue for such Product in such country until the date ten (10) years from the First Commercial Sale.
Sample 1
Length of Royalty Obligations. Each party’s obligations to pay royalties (including without limitation percentages of Sublicense Income) with respect to each Product in each country shall commence on the Royalty Commencement Date for such Product in such country, and shall continue for such Product in such country until (i) if, as of the First Commercial Sale of such Product in such country, there exists a Patent Claim of the applicable Licensed Intellectual Property in the country where such Product is made, used or sold that (A) covers the manufacture, use or sale of such Product, such date as no such Patent Claim exists in the country where such Product is made, used or sold, or (B) covers XenoMouse Animals or their use, such date as no such Patent Claim exists in the country where such Product is made, used or sold, or (ii) otherwise, ten (10) years after the First Commercial Sale of such Product in such country.
Sample 1
AutoNDA by SimpleDocs

Related to Length of Royalty Obligations

  • Duration of Royalty Obligations The royalty obligations of Licensee as to each Product shall terminate on a country-by-country and product-by-product basis concurrently with the expiration of:

  • Royalty Obligations Part 2.7(e) of the Disclosure Schedule contains a complete and accurate list and summary of all royalties, fees, commissions, and other amounts payable by the Seller to any Person (other than sales commissions paid to employees according to the Seller’s standard commissions plan) upon or for the sale, or distribution of any Seller Product or the use of any Seller IP.

  • Third Party Obligations 3.1. The THIRD PARTY shall:-

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Licensee Obligations 3.1 The Licensee is responsible for the installation, operation and maintenance of telecommunication lines, equipment, software and other arrangements necessary for the Licensee to receive the Licensed Data from the LME.

  • Minimum Royalties If royalties paid to Licensor do not reach the minimum royalty amounts stated in Section 3.3 of the Patent & Technology License Agreement for the specified periods, Licensee will pay Licensor on or before the Quarterly Payment Deadline for the last Contract Quarter in the stated period an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties paid to Licensor.

  • Payment of Royalties To the best of Seller’s knowledge, all royalties and in-lieu royalties with respect to the Assets which accrued or are attributable to the period prior to the Effective Time have been properly and fully paid, or are included within the suspense amounts being conveyed to Buyer pursuant to Section 11.4.

  • Supply Obligations Upon Licensor’s request, AbbVie shall either (a) to the extent allowable under such agreements, assign to Licensee or its Affiliates the portion of AbbVie’s agreement(s) with its Third Party manufacturing provider related to the Terminated Antibodies, Terminated Products and placebo used in connection therewith, or alternatively, use Commercially Reasonable Efforts to facilitate Licensor’s entering into a direct supply agreement with such Third Party manufacturing provider of the Terminated Antibodies, Terminated Products and placebo used in connection therewith on comparable terms to those between AbbVie and such Third Party manufacturing provider (in each case assuming AbbVie is then obtaining supply of Terminated Antibodies, Terminated Products or placebo used in connection therewith from a Third Party manufacturing provider) and (b) to the extent AbbVie or its Affiliate is producing its own supply of the Terminated Product, Terminated Antibody or placebo, use Commercially Reasonable Efforts to supply to Licensor the Terminated Antibodies and/or Terminated Products and placebo as requested by Licensor, to the extent reasonably necessary for Licensor’s continued Development and Commercialization of such Terminated Antibodies and/or Terminated Products, until the date on which Licensor notifies AbbVie in writing that Licensor has secured an alternative manufacturer for the Terminated Antibodies and/or Terminated Products, but in no event more for than [***] after the effective date of any expiration or termination of this Agreement. In the case of (b), Licensor shall pay to AbbVie a transfer price for the materials supplied equal to the Manufacturing Cost thereof. Without limiting the foregoing, in either case Licensor shall additionally have the right to immediately have AbbVie commence the transfer of the Manufacturing Process to Licensor or its designee, with such transfer to be carried out in accordance with the terms of Section 3.5.3, applied mutatis mutandis. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.

  • Earned Royalty In addition to the annual license maintenance fee, ***** will pay Stanford earned royalties (Y%) on Net Sales as follows:

  • Royalty Payments (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!